Janssen Biotech, Inc.

Xencor, Inc.

Fei Shen

John R Desjarlais

Gregory L Moore

Sanjaya Singh

Jinquan Luo

Rajkumar Ganesan

Michael Hedvat

Juan Diaz

Adam Zwolak

Sathyadevi Venkataramani

Theresa Marie McDevitt

Sherry La Porte

Fang Yi

Veronica Gusti Zeng

Raymond Brittingham

Matthew Adam Dragovich

Joseph Erhardt

Fouad Moussa

Degang Song

Pankaj Seth

Theresa McDevitt

John Lee

Yonghong Zhao

Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

Anti-CD28 x anti-PSMA antibodies

Provided herein are novel anti-CD28× anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28× anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3× anti-PSMA antibodies) for the treatment of prostate cancers.

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof

Growing community of inventors

Collegeville, PA, United States of America

Fei Shen